Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focusing on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with a ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

Neurogene ( NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a ...

Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome ...

In conclusion, this intriguing report builds on the work of many other groups by further unraveling MECP2 function in the ...

Rett syndrome is caused by mutations of the MECP2 gene located on the X chromosome. Children with Rett initially show typical development before symptoms start. The symptoms vary widely. They ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

A new drug will soon be available to treat Rett syndrome. Amanda Marcotte's daughter is unable to tell whether she's OK with ...